中医临床研究2026，Vol.18Issue(3)：5-12,8.DOI:10.3969/j.issn.1674-7860.2026.03.002
靶向三重奏:C型凝集素样受体2、糖蛋白VI与血小板内皮细胞黏附分子-1作为急性缺血性脑卒中血栓形成与神经炎症的调节靶点
Targeted trio:CLEC-2,GPVI and PECAM1 as regulatory targets of thrombosis and neuroinflammation in acute ischemic stroke
摘要
Abstract
Acute ischemic stroke(AIS)is a kind of neurological disease caused by impaired cerebral blood supply due to various etiologies,resulting in ischemic-hypoxic necrosis of brain tissue and subsequent brain dysfunction.The current reperfusion therapy for AIS faces challenges including a short treatment window and bleeding risks.Research indicates that this neurological disorder may originate from cerebral thrombotic vascular occlusion,with the intrinsic connection between thrombi and pro-inflammatory processes,which provides critical mechanisms for AIS occurrence.Key therapeutic factors in AIS management include C-type lectin-like receptor 2(CLEC-2),glycoprotein VI(GPVI),and platelet endothelial cell adhesion molecule-1(PECAM1),which are promising due to their crucial roles in thrombosis-inflammation crosstalk.However,several key issues remain to be addressed-① Insufficient research depth:The specific mechanisms of CLEC-2,GPVI,and PECAM1 in AIS pathogenesis require systematic elucidation,particularly regarding integration with modern pathophysiological frameworks.② Clinical study standardization gaps:Most trials are limited by small sample sizes and lack standardized protocols,limiting result reliability and reproducibility.Future efforts should focus on investigating receptor mechanisms during hypoxia,identifying key kinases that regulate PECAM1's pro-inflammatory functions,developing inhibitors that effectively target GPVI and CLEC-2 while enhancing PECAM1-mediated vascular protection,and establishing scientific patient stratification systems.Dynamic monitoring of sGPVI and sPECAM1 concentrations could help precisely identify high-risk patients for thrombotic and inflammatory responses,thereby enabling the creation of targeted drug delivery systems to provide more accurate clinical guidance.关键词
血栓-炎症/急性缺血性脑卒中/血小板活化因子Key words
Thrombosis-inflammation/Acute ischemic stroke/Platelet activating factor分类
医药卫生引用本文复制引用
赵悠然,张敬华..靶向三重奏:C型凝集素样受体2、糖蛋白VI与血小板内皮细胞黏附分子-1作为急性缺血性脑卒中血栓形成与神经炎症的调节靶点[J].中医临床研究,2026,18(3):5-12,8.基金项目
国家自然科学基金委员会面上项目(82371360):基于RNF6/p62-Ub介导的选择性自噬探究CXCL13致多发性硬化血脑/脊髓屏障损伤的作用和机制 （82371360）
江苏省中医药管理局科技发展专项(2020ZX17):帕金森病前驱期人群中医体质、经络特点和演变规律及早期干预的多中心临床研究 （2020ZX17）
南京市卫生健康委员会南京市中医药青年人才培养计划(ZYQ2004) （ZYQ2004）
江苏省中医药管理局(MS2024044):调气通腑方对脑梗死急性期痰热腑实证肠道屏障功能的临床及机制研究 （MS2024044）
江苏省中医药学会(ZXF2024020):基于VEGF/PI3K/AKT通路调控血管新生探讨丹芎橘明饮对MCAO大鼠神经保护的作用机制研究 （ZXF2024020）
江苏省研究生科研与实践创新计划(SJCX25_1040):基于血小板活化因子的变化分析丹芎橘明饮治疗缺血性中风急性期风痰阻络证患者的临床疗效. （SJCX25_1040）
